Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death

Zumin Shi, Carole B. Pinnock, Stephen Kinsey-Trotman, Martin Borg, Kim L. Moretti, Scott Walsh, Tina Kopsaftis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background and purpose To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1-Q4) were -4.17, -1.29, -0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1-Q4 hazard ratios (HR) being 3.82 (1.46-10.00), 3.07 (1.10-8.58), 1, 5.15 (1.99-13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07-2.98), 1.55 (0.93-2.59), 1.00 and 1.74 (1.04-2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies.

LanguageEnglish
Pages129-133
Number of pages5
JournalRadiotherapy and Oncology
Volume107
Issue number2
DOIs
Publication statusPublished - May 2013

Keywords

  • Australia
  • Cohort study
  • Mortality
  • Prostate specific antigen velocity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Shi, Z., Pinnock, C. B., Kinsey-Trotman, S., Borg, M., Moretti, K. L., Walsh, S., & Kopsaftis, T. (2013). Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death. Radiotherapy and Oncology, 107(2), 129-133. https://doi.org/10.1016/j.radonc.2013.03.030
Shi, Zumin ; Pinnock, Carole B. ; Kinsey-Trotman, Stephen ; Borg, Martin ; Moretti, Kim L. ; Walsh, Scott ; Kopsaftis, Tina. / Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death. In: Radiotherapy and Oncology. 2013 ; Vol. 107, No. 2. pp. 129-133.
@article{b9461cc07413469d8690817ce1f8c4bf,
title = "Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death",
abstract = "Background and purpose To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1-Q4) were -4.17, -1.29, -0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1-Q4 hazard ratios (HR) being 3.82 (1.46-10.00), 3.07 (1.10-8.58), 1, 5.15 (1.99-13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07-2.98), 1.55 (0.93-2.59), 1.00 and 1.74 (1.04-2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies.",
keywords = "Australia, Cohort study, Mortality, Prostate specific antigen velocity",
author = "Zumin Shi and Pinnock, {Carole B.} and Stephen Kinsey-Trotman and Martin Borg and Moretti, {Kim L.} and Scott Walsh and Tina Kopsaftis",
year = "2013",
month = "5",
doi = "10.1016/j.radonc.2013.03.030",
language = "English",
volume = "107",
pages = "129--133",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Shi, Z, Pinnock, CB, Kinsey-Trotman, S, Borg, M, Moretti, KL, Walsh, S & Kopsaftis, T 2013, 'Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death', Radiotherapy and Oncology, vol. 107, no. 2, pp. 129-133. https://doi.org/10.1016/j.radonc.2013.03.030

Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death. / Shi, Zumin; Pinnock, Carole B.; Kinsey-Trotman, Stephen; Borg, Martin; Moretti, Kim L.; Walsh, Scott; Kopsaftis, Tina.

In: Radiotherapy and Oncology, Vol. 107, No. 2, 05.2013, p. 129-133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death

AU - Shi, Zumin

AU - Pinnock, Carole B.

AU - Kinsey-Trotman, Stephen

AU - Borg, Martin

AU - Moretti, Kim L.

AU - Walsh, Scott

AU - Kopsaftis, Tina

PY - 2013/5

Y1 - 2013/5

N2 - Background and purpose To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1-Q4) were -4.17, -1.29, -0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1-Q4 hazard ratios (HR) being 3.82 (1.46-10.00), 3.07 (1.10-8.58), 1, 5.15 (1.99-13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07-2.98), 1.55 (0.93-2.59), 1.00 and 1.74 (1.04-2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies.

AB - Background and purpose To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1-Q4) were -4.17, -1.29, -0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1-Q4 hazard ratios (HR) being 3.82 (1.46-10.00), 3.07 (1.10-8.58), 1, 5.15 (1.99-13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07-2.98), 1.55 (0.93-2.59), 1.00 and 1.74 (1.04-2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies.

KW - Australia

KW - Cohort study

KW - Mortality

KW - Prostate specific antigen velocity

UR - http://www.scopus.com/inward/record.url?scp=84879021595&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2013.03.030

DO - 10.1016/j.radonc.2013.03.030

M3 - Article

VL - 107

SP - 129

EP - 133

JO - Radiotherapy and Oncology

T2 - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -